Jan 21, 2020
Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8
Jan 14, 2020
ALS Association Makes Multi-Year Commitment to HEALEY ALS Platform Trial
Jan 13, 2020
MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich's Ataxia
Jan 13, 2020
PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference
Jan 09, 2020
Mercaptor Discoveries Announces Preclinical Program in Epilepsy
Jan 09, 2020
Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio(TM)
Jan 07, 2020
Ionis' neurological franchise marks year of achievement
Jan 06, 2020
Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
Dec 24, 2019
Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028
Dec 23, 2019
Allergan Receives U.S. FDA Approval for UBRELVY(TM) for the Acute Treatment of Migraine with or without Aura in Adults
Dec 23, 2019
Kadimastem Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients
Dec 18, 2019
Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm)
Dec 17, 2019
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
Dec 16, 2019
BOTOX® (onabotulinumtoxinA) Celebrates 30 Years of Endless Innovation
Dec 13, 2019
MDA Celebrates FDA Approval of Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping
Dec 13, 2019
ITF Pharma Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIGLUTIK® (riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS) with a Percutaneous Endoscopic Gastronomy (PEG) Feeding Tube
Dec 11, 2019
Philip M. Gattone to Step Down as President & CEO of the Epilepsy Foundation
Dec 10, 2019
Answer ALS and Avanade harness technology to accelerate largest-ever ALS research program
Dec 09, 2019
Muscular Dystrophy Association Names Sharon Hesterlee, Ph.D., Executive Vice President, Chief Research Officer
Dec 09, 2019
HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)